Doctors today hailed a breakthrough in the fight against pancreatic cancer after a new drug was shown to give patients precious extra months of life.
The treatment, daraxonrasib, is the first medicine able to target the genetic mutation that drives 90 per cent of cases – something scientists have spent decades trying to achieve.
Early results show the once daily pill can double survival for people with the deadliest form of the disease.
Experts said the ‘unprecedented’ findings marked a turning point in the fight against the disease, which is one of the hardest cancers to treat.
Around 10,500 people in the UK are
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.
